FDA approved the JAK inhibitor as the first oral medicine for moderate to severe ulcerative colitis, providing Pfizer with fertile new commercial ground for the blockbuster drug.
Pfizer Inc. has secured fertile new commercial ground for its blockbuster rheumatoid arthritis drug Xeljanz (tofactinib) with an expanded US FDA approval in patients with moderately to severely active ulcerative colitis.
FDA approved the janus kinase (JAK) inhibitor Xeljanz for the indication May 30 as expected, following an unanimously positive recommendation...
The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.
Lynkuet will compete with Astellas's Veozah/Veoza
Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
